Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
amitabh das shukla (Allahabad, India), Amitabh Das Shukla, Tariq Mahmood, Alok Chandra, Neha Agrawal. Who is responsible for MDR- TB?. Eur Respir J 2015; 46: Suppl. 59, 1520

Member's Comments

No comment yet.

Related content which might interest you: Why did they get XDR TB ? Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 MDR TB treatment in prison Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002 Treatment options for MDR- and XDR-TB Source: Eur Respir Monogr 2017; 75: 232-244 Year: 2017 The global risk of dying from multidrug-resistant tuberculosis (MDR-TB) Source: International Congress 2014 – Tuberculosis epidemiology: novel features Year: 2014 Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Analysis of multidrug-resistant tuberculosis Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 MDR- and XDR-TB in Germany Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Extensively drug-resistant (XDR) pulmonary tuberculosis in HIV negative cases Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 The MTBDRplus 2.0 for rapid diagnosis of multidrug-resistant tuberculosis among patients with high risk of TB resistance Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Prevalence of MDR TB and XDR TB in a tertiary care hospital in India Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Frequency of risk factors for multi-drug resistant tuberculosis among the patients enrolled at multi-drug resistant clinic in a tertiary care hospital, Pakistan Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014